This suggests that reducing the function of the TNFR1–SP1PR2–CCL2–CCR2–BDNF pathway at any of its steps reduces BDNF levels and reverse alterations in GABAergic neurotransmission in hyperammonemia and likely in patients with hepatic encephalopathy. This evidence concerns the gene BDNF and Hyperammonemia.